Revolution Medicines

Revolution Medicines is a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers and other difficult-to-treat tumors.

Company Info

Sector:Oncology

Headquarters:Redwood City, California, United States

Founded:2014

Website:www.revmed.com/

Upcoming Milestones & Key Dates

2027-H1

Clinical

Daraxonrasib Phase 3 data expected

Clinical Development Pipeline

Daraxonrasib (RMC-6236)

Target: RAS(ON)

RAS-mutated cancers

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Darovasertib (RMC-6291)

Target: GNAQ/GNA11

Metastatic uveal melanoma

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Elironrasib (RMC-5127)

Target: KRAS G12V

KRAS G12V tumors

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Novo vet Uli Stilz settles in at Flagship; Revolution Medicines welcomes commercial exec ↗

Novo vet Uli Stilz settles in at Flagship; Revolution Medicines welcomes commercial exec — Endpoints News coverage of biopharma industry developments.

Leadership Team

Mark Goldsmith

Chief Executive Officer

Jack Anders

Chief Financial Officer

Wei Lin

Chief Medical Officer

Careers & Job Openings

See all open roles

Apply Now →